Serious drug-related TEAEs occurring in ≥ 2 gilteritinib-treated patients were febrile neutropenia (n = 3), increased alanine aminotransferase (ALT; n = 3), increased aspartate aminotransferase (AST; n = 3), and pneumonia (n = 2). This evidence concerns the gene GPT and pneumonia.